论文部分内容阅读
美国生物技术巨头安进(Amgen)与合作伙伴UCB近日公布了骨质疏松症新药romosozumab一项关键性安慰剂对照Ⅲ期研究(BRIDGE)的积极顶线数据,研究结果证实了romosozumab在骨质疏松症男性患者群体中的显著疗效。
US biotech giant Amgen and partner UCB recently released positive top-line data for a pivotal placebo-controlled phase III study (BRIDGE) of the new drug for osteoporosis, romosozumab, which confirmed the role of romosozumab in osteoporosis Symptomatic male patient population significant effect.